🔎 Trials Near Me

Akèy › Osteyosakòm › Massachusetts

Etid klinik pou Osteyosakòm nan Massachusetts

9 etid pou Osteyosakòm ap chèche patisipan nan sit nan Massachusetts.

Vil nan Massachusetts

Tèks ofisyèl etid la (Anglè)

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

  • Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 12 a 39 · Tout sèks · Mizajou Sep 29, 2026 · NCT04616560

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 3
Jiska laj 50 · Tout sèks · Mizajou Aug 25, 2026 · NCT05235165

SPEARHEAD-3 Pediatric Study

  • Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 2 a 21 · Tout sèks · Mizajou Aug 11, 2026 · NCT05642455

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

  • Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Jiska laj 30 · Tout sèks · Mizajou Aug 3, 2026 · NCT06239272

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Dana-Farber Cancer Institute, Boston
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 18, 2026 · NCT01790152

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

  • Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou May 1, 2026 · NCT07357519

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

  • Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Apr 17, 2026 · NCT05019703

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

  • Boston Children's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
  • Brigham and Women's Hospital, Boston
Ap rekriteFaz 1/2
Laj 12 a 49 · Tout sèks · Mizajou Feb 19, 2026 · NCT06709495

Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.